JP2020533338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533338A5 JP2020533338A5 JP2020514273A JP2020514273A JP2020533338A5 JP 2020533338 A5 JP2020533338 A5 JP 2020533338A5 JP 2020514273 A JP2020514273 A JP 2020514273A JP 2020514273 A JP2020514273 A JP 2020514273A JP 2020533338 A5 JP2020533338 A5 JP 2020533338A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- nucleic acid
- protein
- acid construct
- unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims 29
- 102000037865 fusion proteins Human genes 0.000 claims 29
- 102000039446 nucleic acids Human genes 0.000 claims 24
- 108020004707 nucleic acids Proteins 0.000 claims 24
- 150000007523 nucleic acids Chemical class 0.000 claims 24
- 102000004169 proteins and genes Human genes 0.000 claims 23
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 108010041986 DNA Vaccines Proteins 0.000 claims 18
- 229940021995 DNA vaccine Drugs 0.000 claims 18
- 229960005486 vaccine Drugs 0.000 claims 18
- 238000005734 heterodimerization reaction Methods 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- 230000008685 targeting Effects 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 230000000890 antigenic effect Effects 0.000 claims 7
- 239000000833 heterodimer Substances 0.000 claims 7
- 239000000178 monomer Substances 0.000 claims 7
- 241000712461 unidentified influenza virus Species 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 101710154606 Hemagglutinin Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 2
- 101710176177 Protein A56 Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102000025171 antigen binding proteins Human genes 0.000 claims 2
- 108091000831 antigen binding proteins Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000000185 hemagglutinin Substances 0.000 claims 2
- 239000000710 homodimer Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- -1 CD11c Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 102000015789 HLA-DP Antigens Human genes 0.000 claims 1
- 108010010378 HLA-DP Antigens Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 102100022297 Integrin alpha-X Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 102000002067 Protein Subunits Human genes 0.000 claims 1
- 108010001267 Protein Subunits Proteins 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023133426A JP7696169B2 (ja) | 2017-09-07 | 2023-08-18 | ワクチン分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555305P | 2017-09-07 | 2017-09-07 | |
| US62/555,305 | 2017-09-07 | ||
| PCT/IB2018/001119 WO2019048928A1 (en) | 2017-09-07 | 2018-09-07 | VACCINE MOLECULES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133426A Division JP7696169B2 (ja) | 2017-09-07 | 2023-08-18 | ワクチン分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533338A JP2020533338A (ja) | 2020-11-19 |
| JP2020533338A5 true JP2020533338A5 (enExample) | 2021-09-30 |
| JPWO2019048928A5 JPWO2019048928A5 (enExample) | 2023-04-20 |
Family
ID=63857977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514273A Pending JP2020533338A (ja) | 2017-09-07 | 2018-09-07 | ワクチン分子 |
| JP2023133426A Active JP7696169B2 (ja) | 2017-09-07 | 2023-08-18 | ワクチン分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133426A Active JP7696169B2 (ja) | 2017-09-07 | 2023-08-18 | ワクチン分子 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12268736B2 (enExample) |
| EP (1) | EP3678698A1 (enExample) |
| JP (2) | JP2020533338A (enExample) |
| WO (1) | WO2019048928A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021204911A1 (en) * | 2020-04-07 | 2021-10-14 | Evaxion Biotech A/S | Neoepitope immunotherapy with apc targeting unit |
| US20250304626A1 (en) * | 2021-05-26 | 2025-10-02 | Evaxion Biotech A/S | Vaccination targeting intracellular pathogens |
| WO2024100196A1 (en) | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| NZ241954A (en) | 1991-03-15 | 1994-01-26 | Amgen Inc | Compositions of g-csf for pulmonary administration. |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| IT1247472B (it) | 1991-05-31 | 1994-12-17 | Fidia Spa | Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| CA2085827C (en) | 1991-12-23 | 2003-10-14 | Lucas A. T. Hilgers | Adjuvant composition containing synthetic hydrophobic lipopolysaccharide |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| AU685443B2 (en) | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| ES2149340T3 (es) | 1993-11-17 | 2000-11-01 | Om Pharma | Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso. |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| ATE234129T1 (de) | 1996-06-18 | 2003-03-15 | Alza Corp | Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten |
| US6610661B1 (en) | 1996-10-11 | 2003-08-26 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| JP4153999B2 (ja) | 1996-12-20 | 2008-09-24 | アルザ・コーポレーション | 経皮作用剤流量を強化するための組成物と方法 |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| CA2654522C (en) | 1997-08-29 | 2014-01-28 | Antigenics Inc. | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| NZ504894A (en) | 1997-12-02 | 2002-12-20 | Powderject Vaccines Inc | Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique |
| EP2275133A1 (en) | 1999-02-26 | 2011-01-19 | Novartis Vaccines and Diagnostics, Inc. | Use of bioadhesives and adjuvants for the mucosal delivery of antigens |
| US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
| US20050238660A1 (en) | 2001-10-06 | 2005-10-27 | Babiuk Lorne A | Cpg formulations and related methods |
| PT1599504E (pt) | 2003-02-25 | 2015-03-02 | Vaccibody As | Anticorpo modificado |
| JP6091894B2 (ja) | 2009-09-16 | 2017-03-15 | ジェネンテック， インコーポレイテッド | コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用 |
| TR201908199T4 (tr) | 2011-12-21 | 2019-06-21 | Vaccibody As | HPV'ye karşı aşılar. |
| WO2014140176A1 (en) | 2013-03-15 | 2014-09-18 | Vaccibody As | Targeting vaccines for veterinary use |
-
2018
- 2018-09-07 JP JP2020514273A patent/JP2020533338A/ja active Pending
- 2018-09-07 WO PCT/IB2018/001119 patent/WO2019048928A1/en not_active Ceased
- 2018-09-07 US US16/645,140 patent/US12268736B2/en active Active
- 2018-09-07 EP EP18786391.5A patent/EP3678698A1/en active Pending
-
2023
- 2023-08-18 JP JP2023133426A patent/JP7696169B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2976814C (en) | Immunogenic compositions and methods for treating influenza | |
| JP6957580B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| Liu et al. | Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin | |
| Umthong et al. | Immunogenicity of a DNA and recombinant protein vaccine combining LipL32 and Loa22 for leptospirosis using chitosan as a delivery system | |
| JP2013523096A5 (enExample) | ||
| US9963490B2 (en) | Influenza nucleoprotein vaccines | |
| JP2020533338A5 (enExample) | ||
| US20230416311A1 (en) | Influenza vaccines | |
| Arnaboldi et al. | Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague | |
| JP2020502075A (ja) | 肺炎球菌表面プロテインａの選択されたアルファヘリカルドメインおよびプロリンリッチドメインを組み合わせた肺炎球菌ワクチン | |
| US12397050B2 (en) | Universal mammalian influenza vaccine | |
| CN103209990B (zh) | 重组流感病毒血凝素（ha）抗原蛋白和含其的疫苗 | |
| Lee et al. | Attachment of flagellin enhances the immunostimulatory activity of a hemagglutinin-ferritin nano-cage | |
| AU2015330971B2 (en) | Chimeric proteins | |
| Stepanova et al. | A fusion protein based on the second subunit of hemagglutinin of influenza A/H2N2 viruses provides cross immunity | |
| KR102112759B1 (ko) | 페리틴 자가조립체에 항원 펩타이드 및 면역 증강제가 결합된 나노 입자 및 이의 용도 | |
| CN120641124A (zh) | 用对映特异性阳离子脂质r-dotap配制的重组蛋白疫苗及其使用方法 |